{"title":"Drug makers sue FDA so they can keep making knockoff weight-loss drugs","link":"https://arstechnica.com/health/2024/10/drug-makers-sue-fda-so-they-can-keep-making-knockoff-weight-loss-drugs/","date":1728508629000,"content":"<p>Compounding pharmacies are suing the Food and Drug Administration so they can keep making imitation versions of popular—and lucrative—tirzepatide drugs, namely knockoffs of Mounjaro for diabetes and Zepbound for weight loss.</p>\n<p>Generally, compounding pharmacies make customized formulations of drugs for patients with specific needs, like when a patient has an allergy to a filler ingredient or if a child needs a liquid version of a drug that normally comes as a capsule. But larger compounding operations are also legally allowed to make imitations of branded drugs if those drugs are in short supply, acting as a stopgap for patients.</p>\n<p>Tirzepatide has certainly been in short supply in recent years. Given the high prevalence of diabetes and obesity in America and the drug's effectiveness, demand for tirzepatide and other drugs in the new GLP-1 class have skyrocketed, and many patients have struggled to fill prescriptions. The FDA placed tirzepatide on its <a href=\"https://dps.fda.gov/drugshortages\">drug shortage list</a> in December of 2022—and that's where it remained until last week.</p><p><a href=\"https://arstechnica.com/health/2024/10/drug-makers-sue-fda-so-they-can-keep-making-knockoff-weight-loss-drugs/\">Read full article</a></p>\n<p><a href=\"https://arstechnica.com/health/2024/10/drug-makers-sue-fda-so-they-can-keep-making-knockoff-weight-loss-drugs/#comments\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"4dbc2811ae5cb4138adc32445b0461075231b5de5edcff2b59e2fc2a4e1850ba","category":"Tech"}